Melanoma Research Foundation Breakthrough Consortium Inc

Nonprofit profile at a glance

EIN
800671049
IRS 990 coverage
2015–2020
Forms available
Form 990 2020
Location
Washington, DC, USA
Phone
2023479675
Rating
82
Verdict
STRONG
Rating confidence
Moderate
Sector
Cancer

Official website

Reported finances

Revenue
$320,000
Expenses
$314,821
Assets
$0
Liabilities
$0

Source: IRS Form 990. Selected filing: tax year 2020. Amounts in USD.

Leadership & pay

7 people listed

Executive titles in this filing

  • STEVE SILVERSTEIN (CHAIRMAN & PRESIDENT)

People named in this filing

  • STEVE SILVERSTEIN (CHAIRMAN & PRESIDENT)
  • ANTHONY T HENDRICKSON (TREASURER & CFO)
  • MICHAEL B ATKINS MD (BOARD MEMBER)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990. Selected filing: tax year 2020. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

The mission of the melanoma research foundation breakthrough consortium, inc. (the consortium) is to accelerate the research and development of the most promising therapeutics in melanoma in order to deliver curative options to patients. The consortium will develop collaborative, multi-sector partnerships across the breadth of melanoma disciplines - basic, translational and clinical science - to expedite development of combinations of therapies as well as novel single agents; support pre-clinical research to facilitate rational combinations; create a virtual annotated specimen biorepository; and identify biomarkers that have prognostic and predictive value or value as a new therapeutic target.

What it reported doing in 2020

The consortium seeks to accelerate research and development of the most promising therapeutics in melanoma in order to deliver curative options to patients. Success in this endeavor also furthers the exempt purpose of the melanoma research foundation (mrf). In order to achieve its mission, the consortium will develop collaborative, multi-sector partnerships across the breadth of melanoma disciplines- basic, translational and clinical science- to expedite development of combination therapies as well as novel single agents; support preclinical research to facilitate rational combinations; create a virtual annotated specimen biorepository; and identify biomarkers that have prognostic and predictive value or value as new therapeutic targets which required the expertise of a md and project manager. In addition, the consortium's board of directors and participating research institutions will conduct outreach to multi sector partners with an interest or investment in melanoma research to ensure that the consortium is aware of any important developments or promising research in the field of melanoma.

Operating model

Revenue model
Donor-supported. 100% of the money available for current operations came from contributions and gifts.
Distribution model
Grant intermediary. The nonprofit sent 96% of its reported program spending out as grants.

The verdict

STRONG - A large share of available resources goes toward mission work and the filed numbers largely add up. Program spending has declined or grown slowly and revenue has declined or grown slowly.

Rating breakdown

  • Financial Efficiency: 87
  • Transparency & Controls: 94
  • Accountability: 88
  • Sustainability: 26
  • Growth: 0

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 97.7%; rating input score 98
  • Program expense ratio: 99.4%; rating input score 99
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
  • Pay-setting controls: Limited
  • Foreign activity oversight: Limited
  • Grant itemization coverage: 100%; rating input score 100; 79th percentile among comparable filings
  • Major donor itemization: Yes; rating input score 100
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
  • Governance controls: 5 of 7 controls in place; rating input score 71
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Pass
    • Document-retention policy: Pass
    • CEO compensation review process: NotApplicable
    • Other executive compensation review process: NotApplicable
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Missing
    • Independent financial-statement audit: Fail

Sustainability

  • Operating margin: 1.6%; rating input score 37; 37th percentile among comparable filings
  • Total-asset coverage ratio: 0; rating input score 1; 1st percentile among comparable filings
  • Liabilities to assets ratio: Limited
  • Officer compensation ratio: 0%; rating input score 72; 72nd percentile among comparable filings

Growth

  • Program expense growth: -10.3% per year; rating input score 0; 17th percentile among comparable filings
  • Revenue growth: -10.8% per year; rating input score 0; 9th percentile among comparable filings
  • Asset growth: -23.4% per year; rating input score 0; 2nd percentile among comparable filings

Details

  • Where the money goes: 97.7% of revenue deployed · 99.4% of spending went to programs
  • Governance: 7 of 7 board members independent · 5 of 7 filing controls reported
  • Programs: 1 filed program accomplishment · $313K in reported program spending
  • Leadership: top reported pay $0 · 7 people listed
  • Consistency: 15 of 15 current checks pass
  • Schedules: 6 filed schedules · includes major donors and grants
  • Filing history: 6 filing years from 2015 to 2020
  • Contacts: How to reach this organization
  • Money network: 1 filed money-flow record
  • Related organizations: 2 filed related-organization links
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

Grant-readiness screening is separate from the live rating, not a measure of program quality. Review the source records before making a grant decision.

  • High — Growth: Program expense growth scored 0/100.
  • High — Growth: Revenue growth scored 0/100.
  • Moderate — Sustainability: Operating margin scored 37/100.
  • High — Sustainability: Total-asset coverage ratio scored 1/100.
  • Review — Accountability: Governance controls: Independent financial-statement audit not reported.
  • High — Growth: Asset growth scored 0/100.
  • High — Grant Readiness: Automatic revocation: this organization had its federal tax-exempt status automatically revoked.